Oxford Biomedica on track to deliver 2023 revenues of GBP 90M

The company said, “In line with guidance provided at the Interim Results in September, the Company is on track to deliver revenues for the year ending 31 December 2023 of approximately GBP 90 million. Also in line with guidance provided at the Interim Results, Operating EBITDA loss for the second half of 2023 is on track to be approximately GBP 10 million better than the first half. The Company also remains on track to deliver broadly breakeven Operating EBITDA in 2024, bolstered by positive momentum in business development activities and new orders recently secured across lentivirus, adenoviral vectors and AAV, with both new and existing clients. This momentum will further support the Company’s medium term guidance of a three-year revenue CAGR in excess of 30%, and at least a doubling of revenues by the end of 2026. The above guidance excludes the financial impact of the acquisition of ABL Europe SAS. The Company will provide further financial guidance after the completion of this transaction, currently expected in the first quarter of 2024.”